Adding the advanced PET radiotracer fluciclovine to conventional imaging to help guide radiation treatments for recurrent prostate cancer can improve disease-free survival rates, a new study finds. Findings from the randomized phase II/III EMPIRE-1 trial (NCT01666808) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy.
A novel agent that targets a mutated form of the KRAS gene - the most commonly altered oncogene in human cancers and one long considered "undruggable" - shrank tumors in most patients in a clinical trial with manageable side effects, researchers reported today at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutic, which is taking place online.
New results from a clinical trial of a drug that targets a cancer-causing mutation in the KRAS gene have shown that it can shrink tumours and is well-tolerated by patients. In two presentations to the 32nd EORTC-NCI-AACR cancer symposium, researchers involved in the KRYSTAL-1 phase I/II clinical trial said that adagrasib (MRTX849) showed clinical activity and manageable adverse side effects in patients with non-small cell lung cancer, colorectal cancer and other solid tumours.
A new drug designed to work on cancers with an altered BRAF gene has shown promise in an early patient trial presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.
Findings from the largest international research study found that using FIT is almost 100% accurate at ruling out bowel cancer in patients with suspicious symptoms. During COVID, cancer diagnostics services were suspended and continue to be disrupted. Clinicians in London, along with NHS England, London region, agreed to rapidly implement the use of the same easy home test used in the bowel cancer screening programme, the FIT (faecal immunochemical test), to rule out cancer in people with suspected symptoms.
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases.
A medication frequently used to treat diabetic macular edema, which is the most common cause of blindness in people with diabetes, is less effective when used to treat the condition in Black patients, new study results show.
A Purdue University scientist and entrepreneur is working to use simple LED light to help determine if certain chemotherapy options will work for specific patients.
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.